EAM
AIMT

Erste Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Erste Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-20,300
Closed -$468K – 447
2018
Q4 		$468K Buy
+20,300
New +$525K 0.03% 314

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Erste Asset Management's AIMT Position: Q1 2019 in Review

Erste Asset Management sold out of Aimmune Therapeutics (AIMT) in Q1 2019, closing a stake of 20,300 shares — an estimated $468K sold.

Erste Asset Management first reported a position in AIMT in Q4 2018 and held it in 1 quarter. The position peaked at $468K in Q4 2018. 125 funds tracked by Wall St. Rank hold AIMT as of Q1 2019.

  • Erste Asset Management reported no remaining Aimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Erste Asset Management sold 20,300 Aimmune Therapeutics shares in Q1 2019, an estimated $468K.
  • Erste Asset Management first reported a position in Aimmune Therapeutics in Q4 2018 and held it in 1 quarter.
  • Erste Asset Management's Aimmune Therapeutics position peaked at $468K in Q4 2018.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2019.

Based on Erste Asset Management's 13F filing for Q1 2019, filed 22 Nov 2024.